An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy number aberrations, yet the identity of functional drivers resident in many amplicons remain elusive. Here, we implemented a functional genomics approach to identify new oncogenes involved in prostate cancer progression. Through integrated analyses of focal amplicons in large prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen. Among the top positive hits, we conducted an in-depth functional analysis on Pygopus family PHD finger 2 (PYGO2), located in the amplicon at 1q21.3. PYGO2 overexpression enhances primary tumor growth and local invasion to draining lymph nodes. Conversely, PYGO2 depletion inhibits prostate cancer cell invasion in vitro and progression of primary tumor and metastasis in vivo In clinical samples, PYGO2 upregulation associated with higher Gleason score and metastasis to lymph nodes and bone. Silencing PYGO2 expression in patient-derived xenograft models impairs tumor progression. Finally, PYGO2 is necessary to enhance the transcriptional activation in response to ligand-induced Wnt/β-catenin signaling. Together, our results indicate that PYGO2 functions as a driver oncogene in the 1q21.3 amplicon and may serve as a potential prognostic biomarker and therapeutic target for metastatic prostate cancer.Significance: Amplification/overexpression of PYGO2 may serve as a biomarker for prostate cancer progression and metastasis. Cancer Res; 78(14); 3823-33. ©2018 AACR.

[1]  J. Thoms,et al.  PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy , 2017, Journal of Clinical Pathology.

[2]  R. Kypta,et al.  WNT signalling in prostate cancer , 2017, Nature Reviews Urology.

[3]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[4]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[5]  R. DePinho,et al.  Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer , 2017, Nature.

[6]  F. Brembeck,et al.  The role of Pygo2 for Wnt/ß-catenin signaling activity during intestinal tumor initiation and progression , 2016, Oncotarget.

[7]  Qi-cong Luo,et al.  Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway , 2016, Oncogene.

[8]  Charles Swanton,et al.  Metastasis as an evolutionary process , 2016, Science.

[9]  Jun Dai,et al.  Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment , 2016, Scientific Reports.

[10]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[11]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[12]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[13]  S. Zhang,et al.  Pygopus-2 promotes invasion and metastasis of hepatic carcinoma cell by decreasing E-cadherin expression , 2015, Oncotarget.

[14]  M. Rosenfeld,et al.  LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs , 2013, Nature.

[15]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[16]  M. Ittmann,et al.  FGFR1 is essential for prostate cancer progression and metastasis. , 2013, Cancer research.

[17]  N. Nath,et al.  Identification and characterization of small molecule inhibitors of a plant homeodomain finger. , 2012, Biochemistry.

[18]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[19]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[20]  Gerald C. Chu,et al.  Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases , 2012, Cell.

[21]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[22]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[23]  P. Troncoso,et al.  Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features , 2011, Clinical Cancer Research.

[24]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[25]  Qiongqing Wang,et al.  ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. , 2009, Genes & development.

[26]  V. Horsley.  Epigenetics, Wnt signaling, and stem cells: the Pygo2 connection , 2009, The Journal of cell biology.

[27]  Wenyan Lu,et al.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.

[28]  E. Vazquez,et al.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. , 2008, The Journal of clinical investigation.

[29]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[30]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[31]  T. Golub,et al.  Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells , 2004, Cancer Research.

[32]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[35]  I. Weissman,et al.  Wnt proteins are lipid-modified and can act as stem cell growth factors , 2003, Nature.

[36]  Ajamete Kaykas,et al.  Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements , 2003, Current Biology.

[37]  Xinhua Lin,et al.  pygopus Encodes a nuclear protein essential for wingless/Wnt signaling. , 2002, Development.

[38]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[39]  Y. Labrie,et al.  AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells. , 2002, Cancer research.

[40]  H. Moch,et al.  Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization * , 2001, The Prostate.

[41]  H. Tanke,et al.  Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.

[42]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[43]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[44]  F. Saad,et al.  Managing bone metastases and reducing skeletal related events in prostate cancer , 2015, Nature Reviews Clinical Oncology.

[45]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[46]  G. Hampton,et al.  Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. , 2009, Neoplasia.

[47]  田村 賢司.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles , 2007 .

[48]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[49]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.